Overview

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2017-04-07

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Collaborator:

Celgene Corporation

Treatments:

Carboplatin
Pemetrexed